Organon Follistim AQ Clears FDA; Formulation Has Dosing Advantage, Firm Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The ready-to-inject infertility treatment delivers 18% more follitropin beta than a conventional syringe, Organon says. The company also hopes to launch its implantable contraceptive Implanon this year.
You may also be interested in...
Akzo Nobel Pharma In For “Rough Ride” In 2004; Firm Will Rely On Partnering, R&D Investment
Despite expected “hit from lower sales” for pharmaceuticals in 2004, Akzo will continue to invest in R&D as “something stable,” company tells analysts. Potential 2004 launches include Organon’s Implanon and Variza, both pending at FDA.
Akzo Nobel Pharma In For “Rough Ride” In 2004; Firm Will Rely On Partnering, R&D Investment
Despite expected “hit from lower sales” for pharmaceuticals in 2004, Akzo will continue to invest in R&D as “something stable,” company tells analysts. Potential 2004 launches include Organon’s Implanon and Variza, both pending at FDA.
Organon Building New Quality Affairs Group; New Jersey Plant To Close
The West Orange, N.J. facility’s closure will affect 220 employees and result in the discontinuation of three products. Organon hopes to offer 45-50 positions in quality affairs to affected staff.
Need a specific report? 1000+ reports available
Buy Reports
Register for our free email digests: